Cargando…

Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells

Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasia that lacks effective targeted chemotherapies. Clinically, JMML manifests as monocytic leukocytosis, splenomegaly with consequential thrombocytopenia. Most commonly, patients have gain-of-function (GOF) oncogenic mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramdas, Baskar, Yuen, Lisa Deng, Palam, Lakshmi Reddy, Patel, Roshini, Pasupuleti, Santhosh Kumar, Jideonwo, Victoria, Zhang, Ji, Maguire, Callista, Wong, Eric, Kanumuri, Rahul, Zhang, Chujing, Sandusky, George, Chan, Rebecca J., Zhang, Chi, Stieglitz, Elliot, Haneline, Laura, Kapur, Reuben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263321/ https://www.ncbi.nlm.nih.gov/pubmed/35443935 http://dx.doi.org/10.1016/j.ymthe.2022.04.009

Ejemplares similares

Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway
por: Palam, Lakshmi Reddy, et al.
Publicado: (2023)

Driver Mutations in Leukemia Promote Disease Pathogenesis through a Combination of Cell-Autonomous and Niche Modulation
por: Ramdas, Baskar, et al.
Publicado: (2020)

Combined heterozygosity of FLT3(ITD), TET2, and DNMT3A results in aggressive leukemia
por: Ramdas, Baskar, et al.
Publicado: (2022)

Obesity-induced inflammation exacerbates clonal hematopoiesis
por: Pasupuleti, Santhosh Kumar, et al.
Publicado: (2023)

Physioxia-induced downregulation of Tet2 in hematopoietic stem cells contributes to enhanced self-renewal
por: Aljoufi, Arafat, et al.
Publicado: (2022)

Stem cell origins of JMML
por: Sundaravel, Sriram, et al.
Publicado: (2021)

JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β
por: Yan, Yuhan, et al.
Publicado: (2022)

Il-1r1 drives leukemogenesis induced by Tet2 loss
por: Burns, Sarah S., et al.
Publicado: (2022)

Role of intracellular tyrosines in activating KIT induced myeloproliferative disease
por: Ma, Peilin, et al.
Publicado: (2012)

A 27-Year-Old Patient Fulfilling the Diagnostic Criteria of Both CMML and JMML
por: Elghazaly, Assem A., et al.
Publicado: (2016)

Wiskott-Aldrich Syndrome Presenting with JMML-Like Blood Picture and Normal Sized Platelets
por: Patil, Rajesh B., et al.
Publicado: (2016)

PB2046: SHORT-TERM EFFICACY OF DECITABINE IN COMBINATION WITH LOW-DOSE CHEMOTHERAPY IN THE TREATMENT OF JMML: A RETROSPECTIVE STUDY
por: Cai, Y., et al.
Publicado: (2022)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment
por: Caye, Aurélie, et al.
Publicado: (2019)

KMT2A-MLLT3 AML Masquerading as JMML may Disguise Fatal Leukemia
por: Saad, Ashraf Abdullah, et al.
Publicado: (2019)

Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment
por: Caye, Aurélie, et al.
Publicado: (2020)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system
por: Cani, Alice, et al.
Publicado: (2022)

Epigenetic Profiling of PTPN11 Mutant JMML Hematopoietic Stem and Progenitor Cells Reveals an Aberrant Histone Landscape
por: Sinha, Roshani, et al.
Publicado: (2023)

Rapid development of myeloproliferative neoplasm in mice with Ptpn11(D61Y) mutation and haploinsufficient for Dnmt3a
por: Deng, Lisa, et al.
Publicado: (2017)

P1000: JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK
por: Rajak, Jovana, et al.
Publicado: (2023)

Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft
por: Vinci, Luca, et al.
Publicado: (2023)

Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML
por: Zhao, Yuming, et al.
Publicado: (2023)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Hematopoietic Progenitor Hyperproliferation and Malignant Disease In Vivo
por: Nabinger, Sarah C., et al.
Publicado: (2012)

Class I(A) PI3Kinase Regulatory Subunit, p85α, Mediates Mast Cell Development through Regulation of Growth and Survival Related Genes
por: Krishnan, Subha, et al.
Publicado: (2012)

VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease
por: An, Wei, et al.
Publicado: (2016)

Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
por: Zhang, Datong, et al.
Publicado: (2021)

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
por: Richine, Briana M., et al.
Publicado: (2016)

BTK: sensing pathogenic nucleic acids
por: Lee, Koon-Guan, et al.
Publicado: (2015)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment
por: Leoncini, Pier Paolo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tk9jcitvi0h9cot028ph3r0dou